Patents by Inventor Tobias LITZENBURGER

Tobias LITZENBURGER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
    Publication number: 20240124604
    Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.
    Type: Application
    Filed: December 26, 2023
    Publication date: April 18, 2024
    Applicant: AltruBio Inc.
    Inventors: Stefan Bassarab, Barbara Enenkel, Patrick Garidel, Heidrun Schott, Sanjaya Singh, Tobias Litzenburger
  • Anti-PSGL-1 antibodies and uses thereof
    Patent number: 11897964
    Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: February 13, 2024
    Assignee: AltruBio Inc.
    Inventors: Stefan Bassarab, Barbara Enenkel, Patrick Garidel, Heidrun Schott, Sanjaya Singh, Tobias Litzenburger
  • ANTI-CD40 ANTIBODIES
    Publication number: 20220153857
    Abstract: The present invention related to new humanized antanogistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: February 7, 2022
    Publication date: May 19, 2022
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca BARRETT, Scott Ronald BRODEUR, Keith CANADA, Tobias Litzenburger, Sanjaya Singh
  • Anti-CD40 antibodies
    Patent number: 11242394
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: February 8, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh
  • ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
    Publication number: 20210395383
    Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.
    Type: Application
    Filed: August 30, 2021
    Publication date: December 23, 2021
    Applicant: AltruBio Inc.
    Inventors: Stefan Bassarab, Barbara Enenkel, Patrick Garidel, Heidrun Schott, Sanjaya Singh, Tobias Litzenburger
  • ANTI-CD40 ANTIBODIES
    Publication number: 20190169301
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: July 10, 2018
    Publication date: June 6, 2019
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh
  • ANTI-CD40 ANTIBODIES
    Publication number: 20170058039
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: November 2, 2016
    Publication date: March 2, 2017
    Inventors: Rachel Rebecca BARRETT, Scott Ronald BRODEUR, Keith CANADA, Tobias LITZENBURGER, Sanjaya SINGH
  • Dabigatran antidotes
    Patent number: 9499633
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: November 22, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Tobias Litzenburger, Herbert Nar, Felix Schiele, Daniel Seeliger, Joanne Van Ryn
  • ANTI-CD40 ANTIBODIES
    Publication number: 20160222124
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: April 14, 2016
    Publication date: August 4, 2016
    Inventors: Rachel Rebecca BARRETT, Scott Ronald BRODEUR, Keith CANADA, Tobias LITZENBURGER, Sanjaya SINGH
  • ANTIBODIES FOR GUANYLYL CYCLASE RECEPTORS
    Publication number: 20160168251
    Abstract: Monoclonal antibodies that act as potentiators, stimulators and agonists of guanylyl cyclase receptors are disclosed.
    Type: Application
    Filed: June 19, 2015
    Publication date: June 16, 2016
    Inventors: Alisa WATERMAN, Daniel RAJOTTE, Tobias LITZENBURGER, Alexandra KRAUS
  • ANTI-CD40 ANTIBODIES
    Publication number: 20150315282
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: June 18, 2015
    Publication date: November 5, 2015
    Inventors: Rachel Rebecca BARRETT, Scott Ronald BRODEUR, Keith CANADA, Tobias LITZENBURGER, Sanjaya SINGH
  • ANTICOAGULANT ANTIDOTES
    Publication number: 20150210778
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Application
    Filed: April 13, 2015
    Publication date: July 30, 2015
    Inventors: Joanne VAN RYN, John Edward PARK, Norbert HAUEL, Ulrich KUNZ, Tobias LITZENBURGER, Keith CANADA, Sanjaya SINGH, Alisa K. WATERMAN
  • Polynucleotides encoding anti-CD40 antibodies
    Patent number: 9090696
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: July 28, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh
  • Antibodies for guanylyl cyclase receptors
    Patent number: 9090695
    Abstract: Monoclonal antibodies that act as potentiators, stimulators and agonists of guanylyl cyclase receptors are disclosed.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: July 28, 2015
    Assignee: MorphoSys AG
    Inventors: Alisa Waterman, Daniel Rajotte, Tobias Litzenburger, Alexandra Kraus
  • Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds
    Patent number: 9034822
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: May 19, 2015
    Assignee: Boehringer Igelheim International GmbH
    Inventors: Joanne Van Ryn, John Edward Park, Norbert Hauel, Ulrich Kunz, Tobias Litzenburger, Keith Canada, Sanjaya Singh, Alisa Waterman
  • ANTICOAGULANT ANTIDOTES
    Publication number: 20150118225
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Application
    Filed: October 23, 2014
    Publication date: April 30, 2015
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Tobias LITZENBURGER, Herbert NAR, Felix SCHIELE, Daniel SEELIGER, Joanne VAN RYN
  • ANTICOAGULANT ANTIDOTES
    Publication number: 20140377265
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Application
    Filed: July 22, 2014
    Publication date: December 25, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Joanne VAN RYN, Keith CANADA, Robert COPENHAVER, Norbert HAUEL, Tobias LITZENBURGER, Christopher Ronald SARKO, Sanjaya SINGH, Alisa K. WATERMAN
  • Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds and methods of use thereof
    Patent number: 8821871
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: September 2, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joanne Van Ryn, Keith Canada, Robert Copenhaver, Norbert Hauel, Tobias Litzenburger, Christopher Ronald Sarko, Sanjaya Singh, Alisa K. Waterman
  • ANTI-CD40 ANTIBODIES
    Publication number: 20140179907
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: October 4, 2013
    Publication date: June 26, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Rachel Rebecca BARRETT, Scott Ronald BRODEUR, Keith CANADA, Tobias LITZENBURGER, Sanjaya SINGH
  • Anti-CD40 antibodies
    Patent number: 8591900
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: November 26, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh